natgillin/translations-raw huggingface dataset:
In a study involving 507 adults with metastatic gastric cancer, patients treated with Lonsurf lived on average for 5.7 months compared with 3.6 months for patients who received placebo. 
V študiji, ki je vključevala 570 odraslih z metastatskim rakom želodca, so bolniki, ki so prejemali zdravilo Lonsurf, živeli povprečno 5,7 meseca v primerjavi s 3,6 meseca pri bolnikih, ki so prejemali placebo.
Lonsurf is a medicine used to treat adults with colorectal cancer (cancer of the large bowel) and gastric (stomach) cancer. 
Lonsurf je zdravilo, ki se uporablja za zdravljenje odraslih s kolorektalnim rakom (rakom debelega črevesa) in rakom želodca.
An overview of Lonsurf and why it is authorised 
Pregled zdravila Lonsurf in zakaj je odobreno v EU
For the full list of side effects and restrictions of Lonsurf, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Lonsurf glejte navodilo za uporabo.
How does Lonsurf work? 
Kako zdravilo Lonsurf deluje?
As a result, trifluridine interferes with DNA function and prevents the cells from dividing to make more cells. 
Tako moti delovanje DNK ter prepreči delitev in razmnoževanje celic.
The doctor may reduce the dose or interrupt treatment if certain side effects develop. 
V primeru določenih neželenih učinkov bo zdravnik morda zmanjšal odmerek ali začasno prekinil zdravljenje.
The Agency considered that the benefit of Lonsurf in prolonging survival in patients with metastatic colorectal and metastatic gastric cancer who have received previous treatment was important. 
Menila je, da so koristi zdravila Lonsurf pri podaljšanju preživetja bolnikov z metastatskim kolorektalnim rakom in metastatskim rakom želodca, ki so se predhodno že zdravili, klinično pomembne.
Lonsurf contains the active substances trifluridine and tipiracil. 
Zdravilo Lonsurf vsebuje učinkovini trifluridin in tipiracil.
How is Lonsurf used? 
Kako se zdravilo Lonsurf uporablja?
Lonsurf prolonged overall survival of patients with metastatic colorectal cancer and in patients with metastatic gastric cancer. 
Zdravilo Lonsurf je podaljšalo celokupno preživetje bolnikov z metastatskim kolorektalnim rakom, ki so predhodno prejemali druga zdravila.
Date of first authorisation: 19 May 2006 Date of latest renewal: 11 February 2016 
Datum prve odobritve: 19. maj 2006 Datum zadnjega podaljšanja: 11. februar 2016
Average VE§ 
Povprečna VE§
VE over study period‡ 
VE v obdobju študije‡
North Carolina 27712 U.S.A 
North Carolina 27712 ZDA
• if you have or have had any medical problems or any allergies 
• če imate ali ste kdaj imeli kakršne koli zdravstvene težave ali alergije,
d. Special populations 
d. Posebne populacije
Some of these reactions may be serious and may include difficulty in breathing or swallowing. 
Nekatere od teh reakcij so lahko hude in lahko vključujejo težave z dihanjem ali požiranjem.
e. Other studies 
e. Druge študije
VZV-seronegative adults 
VZV-seronegativni odrasli
It may lead to severe and long-lasting pain and scarring. 
Lahko povzroči hudo in dolgotrajno bolečino in brazgotinjenje.
VE % (95% CI) 
VE % (95 % IZ)
• if you have HIV infection 
• če imate okužbo z virusom HIV.
286 subjects received two doses and 9 subjects received only one dose. 
286 oseb je prejelo dva odmerka, 9 oseb pa le en odmerek.
See sections 4.3 and 4.4. 
Glejte poglavji 4.3 in 4.4.
Sometimes, after many years, the virus becomes active again and causes shingles. 
Včasih po več letih virus postane znova aktiven in povzroči pasovec.
Inject the vaccine. 
Cepivo injicirajte.
The safety and efficacy of ZOSTAVAX in children and adolescents have not been established. 
Varnost in učinkovitost cepiva ZOSTAVAX pri otrocih in mladostnikih nista bili dokazani.
Read all of this leaflet carefully before you are vaccinated because it contains important information for you. 
Pred cepljenjem natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this vaccine. 
O neželenih učinkih lahko poročate tudi neposredno na nacionalni center za poročanje, ki je naveden v Prilogi V. S tem, ko poročate o neželenih učinkih, lahko prispevate k zagotovitvi več informacij o varnosti tega cepiva.
The requirements for submission of periodic safety update reports for this medicinal products are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
The adverse reactions are assigned frequency categories using the following convention: Very Common (≥1/10); 
Kategorije pogostnosti neželenih učinkov so opredeljene po naslednjem dogovoru: Zelo pogosti (≥ 1/10)
If you have an allergic reaction, call your doctor right away. 
Če imate alergijsko reakcijo, se takoj posvetujte z zdravnikom.
After the shingles blisters heal, pain can last for months or years and may be severe. 
Ko se pasovec (izpuščaj) zaceli, lahko bolečina traja še mesece ali leta in je lahko huda.
Vaccine efficacy (95% CI) 
Učinkovitost cepiva (95 % IZ)
The other ingredients are: 
Druge sestavine cepiva so:
As these events are reported voluntarily from a population of uncertain size, it is not possible to reliably calculate their frequency or establish a causal relationship to vaccine exposure. 
Ker gre za dogodke, o katerih so poročali prostovoljno iz populacije neznane velikosti, ni mogoče zanesljivo izračunati njihove pogostnosti ali ugotoviti vzročne povezave z izpostavljenostjo cepivu.
• if you have a blood disorder or any type of cancer that weakens your immune system 
• če imate krvno bolezen ali katero koli vrsto raka, ki je oslabil vaš imunski sistem,
This vaccine may contain traces of neomycin. 
To cepivo lahko v sledeh vsebuje neomicin.
In clinical trials, general safety has been evaluated in more than 57,000 adults vaccinated with ZOSTAVAX. 
V kliničnih preskušanjih so splošno varnost ocenili pri več kot 57.000 odraslih, cepljenih s cepivom ZOSTAVAX.
• Active untreated tuberculosis. 
• Aktivna, nezdravljena tuberkuloza.
Reconstitution instructions intended for healthcare professionals are included at the end of the leaflet. 
Navodila za pripravo cepiva, namenjena zdravstvenemu osebju, se nahajajo na koncu navodila.
However, data collected in a large observational study did not indicate increased risk for developing herpes zoster after concomitant administration of the two vaccines. 
Toda podatki, zbrani v obsežni opazovalni študiji, niso pokazali večjega tveganja za pojav herpesa zostra po sočasni uporabi obeh cepiv.
Rarely (may affect up to 1 in 1,000 people), allergic reactions may occur. 
Redko (pojavijo se lahko pri največ 1 od 1.000 oseb) se lahko pojavijo alergijske reakcije.
Neomycin allergy generally manifests as a contact dermatitis. 
Alergija na neomicin se običajno pokaže kot kontaktni dermatitis.
Less commonly, bacterial skin infections, weakness, muscle paralysis, loss of hearing or vision can occur. 
Manj pogosto se lahko pojavijo še bakterijske okužbe kože, oslabelost, mišična paraliza in izguba sluha ali vida.
Produced in human diploid (MRC-5) cells 
Pridobljen na humanih diploidnih (MRC-5) celicah.
Adverse events were followed up to Day 42 post vaccination and serious adverse events throughout the entire study period (i.e. through Day 180). 
Neželene učinke so spremljali do 42. dne po cepljenju, resne neželene učinke pa med celotnim obdobjem študije (tj. do 180. dne).
What ZOSTAVAX is and what it is used for 
Kaj je cepivo ZOSTAVAX in za kaj ga uporabljamo
Shingles Prevention Study (SPS) 
Študija preprečevanja pasovca (SPS)
Pharmacotherapeutic group: Vaccines, Viral Vaccine; ATC code: J07BK02 
Farmakoterapevtska skupina: Cepiva, virusna cepiva, oznaka ATC: J07BK02
Data from a clinical trial (n=368) demonstrated that the current refrigerated formulation has a safety profile comparable to that of the frozen formulation. 
Podatki iz kliničnega preskušanja (n = 368) kažejo, da ima sedanja oblika, ki se shranjuje v hladilniku, varnostni profil, primerljiv s tistim za zamrznjeno obliko.
Avoid contact with disinfectants as they may inactivate the vaccine virus. 
Preprečite stik z razkužili, ker lahko inaktivirajo virus v cepivu.
Most of the reporting rashes that were VZV positive by PCR analysis were associated with wild-type VZV. 
Večina poročanih izpuščajev, ki je bila VZV pozitivna po PCR analizi, je bila povezana z divjim tipom VZV.
The European Medicines Agency has waived the obligation to submit the results of studies with ZOSTAVAX in all the subsets of paediatric population (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij s cepivom ZOSTAVAX za vse podskupine pediatrične populacije (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Name and address of the manufacturers of the biological active substances 
Ime in naslov izdelovalcev bioloških učinkovin
Abbreviations: VE denotes vaccine effectiveness; CI confidence interval; DxCG diagnostic cost group; HCUP healthcare cost and utilization project 
Okrajšave: VE - učinkovitost cepiva; IZ - interval zaupanja; DxCG - skupina diagnostičnih stroškov; HCUP - stroški zdravstvenega varstva in projekt utilizacije
• if you are pregnant (in addition, pregnancy should be avoided for 1 month after vaccination, see 
• če ste noseči (poleg tega ne smete zanositi 1 mesec po cepljenju, glejte Nosečnost in dojenje).
Final determination of zoster cases was made by Polymerase Chain Reaction (PCR) [86%], or in the absence of virus detection, as determined by a clinical evaluation committee [14%]. 
Primere herpesa zostra so dokončno potrdili z uporabo verižne reakcije s polimerazo (PCR) [86 %] ali v odsotnosti virusne detekcije s potrditvijo kliničnega ocenjevalnega odbora [14 %].
Consequently, the frequencies of these adverse reactions have been estimated based on the adverse events reported in SPS and ZEST (regardless of vaccine relationship assigned by the investigator). 
Posledično so pogostnosti teh neželenih učinkov ocenjene na podlagi neželenih učinkov, o katerih so poročali v študijah SPS in ZEST (ne glede na povezavo s cepivom, določeno s strani raziskovalca).
A total of 48,889 confirmed HZ cases and 3,316 confirmed PHN cases (>90 days of zoster-associated pain) were observed. 
Opazili so skupaj 48.889 potrjenih primerov HZ ter 3.316 potrjenih primerov PHN (> 90 dni bolečine, povezane s herpes zostrom).
See sections 4.8 and 5.1. 
Glejte poglavji 4.8 in 5.1.
No data are currently available regarding concomitant use with other vaccines. 
Podatkov o sočasni uporabi z drugimi cepivi trenutno ni na voljo.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALCI BIOLOŠKIH UČINKOVIN IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ
This is a theoretical risk for vaccination with ZOSTAVAX. 
To je teoretično tveganje, ki obstaja tudi pri cepljenju s cepivom ZOSTAVAX.
This long-lasting nerve pain is called post-herpetic neuralgia or PHN. 
Ta dolgotrajna bolečina živca se imenuje postherpetična nevralgija ali PHN.
Individuals should receive a single dose (0.65 mL). 
Oseba mora prejeti enkraten odmerek (0,65 ml).
Varicella-zoster virus 
Virus varicella-zoster
In an interim analysis of the 2007 to 2014 study period, out of 1,355,720 study individuals, 392,677 received ZOSTAVAX. 
Pri vmesni analizi iz obdobja študije med leti 2007 in 2014 je od 1.355.720 posameznikov, ki so bili vključeni v študijo, cepivo ZOSTAVAX prejelo 392.677 posameznikov.
The following side effects have been observed: 
Opazili so naslednje neželene učinke:
• if you are allergic (hypersensitive) to any of the components of this vaccine (including neomycin or any of the other ingredients listed in section 6) 
• če ste alergični (preobčutljivi) na katero koli sestavino tega cepiva (vključno z neomicinom ali katero koli drugo sestavino, navedeno v poglavju 6),
• Pregnancy. 
• Nosečnost.
However, a history of contact dermatitis due to neomycin is not a contraindication to receiving live virus vaccines. 
Vendar pa kontaktni dermatitis zaradi neomicina v anamnezi ni kontraindikacija za cepiva z živimi virusi.
3-year postvaccination 5-year postvaccination 
3 leta po cepljenju 5 let po cepljenju
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before receiving this vaccine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden boste cepljeni s tem cepivom.
Store and transport refrigerated (2 C - 8 C). 
Shranjujte in prevažajte v hladilniku (2 ºC - 8 ºC).
Manufacturer: Merck Sharp and Dohme, B.V., Waarderweg, 39, 2031 BN Haarlem, The Netherlands 
Izdelovalec: Merck Sharp and Dohme, B.V., Waarderweg, 39, 2031 BN Haarlem, Nizozemska
The persistence of protection following vaccination has been evaluated through longer-term follow-up in Short-term Persistence Substudy (STPS) and Long-term Persistence Substudy (LTPS) and supports the continued benefit of ZOSTAVAX throughout the follow-up periods studied. 
Trajanje zaščite po cepljenju so ocenili v dolgoročnem spremljanju v podštudiji STPS (Short-term Persistence Substudy) in podštudiji LTPS (Long-term Persistence Substudy) in je podprlo trajno korist cepiva ZOSTAVAX v proučevanih obdobjih spremljanja.
In the SPS, the reduction in zoster was seen in almost all dermatomes. 
V študiji SPS so opazili zmanjšanje herpesa zostra na skoraj vseh dermatomih.
The results showed that ZOSTAVAX is effective in reducing HZ and PHN incidence in vaccinated individuals as compared to an unvaccinated reference group. 
Rezultati kažejo, da je cepivo ZOSTAVAX učinkovito pri zmanjšanju pojavnosti HZ in PHN pri cepljenih osebah v primerjavi z necepljeno referenčno skupino.
Like all vaccines and medicines, this vaccine can cause side effects, although not everybody gets them. 
Kot vsa cepiva in zdravila ima lahko tudi to cepivo neželene učinke, ki pa se ne pojavijo pri vseh osebah.
Vaccine effectiveness (VE) against HZ was evaluated for up to eight years postvaccination. 
Učinkovitost cepiva (VE - Vaccine effectiveness) proti HZ je bila ovrednotena v obdobju do 8 let po cepljenju.
The need for a booster dose is not known. 
Ni znano, ali je potreben obnovitveni odmerek.
VE against PHN was evaluated for up to eight years postvaccination. 
VE proti PHN je bila ovrednotena v obdobju do 8 let po cepljenju.
No serious vaccine-related adverse experiences were reported. 
O resnih neželenih učinkih, povezanih s cepivom, niso poročali.
The two vaccines should be given as separate injections at different body sites. 
Cepivi se morata dajati v ločenih injekcijah in na različne dele telesa.
A decision must be made whether to discontinue breast-feeding or to not administer ZOSTAVAX taking into account the benefit of breast-feeding for the child and the benefit of vaccination for the woman. 
Odločiti se je treba med prenehanjem dojenja in neuporabo cepiva ZOSTAVAX, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti cepljenja za mater.
Necrotizing retinitis (patients on immunosuppressive therapy) 
Bolezni oči nekrotizirajoči retinitis (bolniki na imunosupresivnem zdravljenju)
Other medicines and ZOSTAVAX 
Druga zdravila in cepivo ZOSTAVAX
*The analysis was performed on the intent-to-treat (ITT) population that included all subjects randomised in the ZEST study 
*Analiza je bila opravljena na populaciji z-namenom-zdravljenja (ITT), ki je zajela vse osebe, randomizirane v študiji ZEST.
This risk appears to be causally related to a decline in VZV-specific immunity. 
Tveganje je domnevno vzročno povezano s slabljenjem imunosti, specifične za VZV.
ZOSTAVAX is available in packs of 1, 10 or 20 with or without needles. 
Cepivo ZOSTAVAX je na voljo v pakiranjih po 1, 10 ali 20 z ali brez igle.
ZOSTAVAX Efficacy and Safety Trial (ZEST) in subjects 50 to 59 years of age: 
Preskušanje učinkovitosti in varnosti cepiva ZOSTAVAX (ZEST - ZOSTAVAX Efficacy and Saftey Trial) pri osebah, starih od 50 do 59 let:
The VZV-specific immune responses following Doses 1 and 2 were similar (see section 4.3). 
Imunski odziv, specifičen za VZV, je bil podoben po 1. in 2. odmerku (glejte poglavje 4.3).
After reconstitution, use immediately or within 30 minutes if stored at 20°C-25°C. 
Po pripravi uporabite takoj ali v 30 minutah, če ste cepivo hranili pri temperaturi 20 ºC - 25 ºC.
What you need to know before you receive ZOSTAVAX 
Kaj morate vedeti, preden boste cepljeni s cepivom ZOSTAVAX
• if you have active untreated tuberculosis 
• če imate aktivno, nezdravljeno tuberkulozo,
ZOSTAVAX should be injected under the skin or into the muscle, preferably in the upper arm. 
Cepivo ZOSTAVAX je treba injicirati pod kožo ali v mišico, po možnosti v zgornji predel roke.
However, ZOSTAVAX is expected to have no or negligible influence on ability to drive and use machines. 
Vendar se pri cepivu ZOSTAVAX pričakuje, da nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. 
Zaradi pomanjkanja študij kompatibilnosti cepiva ne smemo mešati z drugimi zdravili (cepivi).
The solvent is a clear and colourless liquid. 
Vehikel je bistra, brezbarvna tekočina.
The majority of rashes have been rated as mild to moderate; no complications from rash have been observed in the clinical setting. 
Večina izpuščajev je bila ocenjena kot blagih do zmernih; zapletov z izpuščajem v kliničnem okolju niso opazili.
In the LTPS, there were 263 evaluable zoster cases reported among 261 patients [10.3/1000 person-years]. 
Tekom študije LTPS so med 261 bolniki zabeležili 263 primerov herpesa zostra, ki jih je bilo možno ovrednotiti [10,3/1.000 oseb-let].
There is no relevant use of ZOSTAVAX in children and adolescents for prevention of primary varicella infection (chickenpox). 
Cepivo ZOSTAVAX ni namenjeno za uporabo pri otrocih in mladostnikih za preprečevanje primarne okužbe z virusom varicella (noric).
ZOSTAVAX can be administered concomitantly with inactivated influenza vaccine as separate injections and at different body sites (see section 5.1). 
Cepivo ZOSTAVAX se lahko daje sočasno s cepivi proti gripi z inaktiviranimi virusi v ločenih injekcijah in na različne dele telesa (glejte poglavje 5.1).
It is recommended that the vaccine be administered immediately after reconstitution to minimise loss of potency. 
Priporočamo, da cepivo aplicirate takoj po rekonstituciji, da se zmanjša možnost izgube učinkovitosti.
No studies on the effects on the ability to drive or use machines have been performed. 
Študij o vplivu na sposobnost vožnje in upravljanja strojev niso izvedli.
† PHN was defined as zoster-associated pain rated as ≥3 (on a 0-10 scale), persisting or appearing more than 90 days after onset of zoster rash using Zoster Brief Pain Inventory (ZBPI). 
† PHN je bila opredeljena kot bolečina, povezana s herpesom zostrom, ocenjena z ≥ 3 (na lestvici od 0 do 10), ki je trajala ali se je pojavila več kot 90 dni po nastanku izpuščaja herpesa zostra (z uporabo lestvice ZBPI [Zoster Brief Pain Inventory]).
Within SPS, immune responses to vaccination were evaluated in a subset of the enrolled subjects (N=1395). 
V študiji SPS so imunski odziv na cepljenje vrednotili pri podskupini vključenih oseb (N = 1.395).
The concomitant use of ZOSTAVAX and a 23-valent pneumococcal polysaccharide vaccine resulted in reduced immunogenicity of ZOSTAVAX in a small clinical trial. 
Sočasna uporaba cepiva ZOSTAVAX in 23-valentnega pnevmokoknega polisaharidnega cepiva je v majhnem kliničnem preskušanju zmanjšala imunogenost cepiva ZOSTAVAX.
This vaccine should be given subcutaneously to individuals with severe thrombocytopenia or any coagulation disorder, because these individuals may bleed following intramuscular injections. 
To cepivo je treba osebam s hudo trombocitopenijo ali kakršno koli motnjo strjevanja krvi dati subkutano, ker se pri takšnih osebah po intramuskularnem injiciranju lahko pojavi krvavitev.
Patients who previously received immune suppressive therapy should be carefully evaluated for the reconstitution of the immune system prior to receiving Zostavax (see section 4.3). 
Bolnike, ki so v preteklosti prejemali imunosupresivno zdravljenje, je treba pred uporabo cepiva ZOSTAVAX skrbno oceniti glede ponovne vzpostavitve imunskega sistema (glejte poglavje 4.3).
For information about the administration of ZOSTAVAX and pneumococcal polysaccharide vaccine at the same time, talk to your doctor or health care provider. 
Za informacije o sočasni uporabi cepiva ZOSTAVAX in pnevmokoknega polisaharidnega cepiva se obrnite na zdravnika ali drugo zdravstveno osebje.
Most of these local and systemic adverse reactions were reported as mild in intensity. 
Večina teh lokalnih in sistemskih neželenih učinkov je bila blagih.
The data do not indicate that concomitant administration alters the effectiveness of ZOSTAVAX. 
Podatki ne kažejo, da bi sočasna uporaba spremenila učinkovitost cepiva ZOSTAVAX.
When evaluated at 4 weeks post-vaccination, the immunogenicity of the current refrigerator-stable formulation was shown to be similar to the immunogenicity of the earlier frozen formulation of ZOSTAVAX. 
Ob vrednotenju štiri tedne po cepljenju se je pokazalo, da je imunogenost sedanje, v hladilniku stabilne oblike, podobna imunogenosti predhodne zamrznjene oblike cepiva ZOSTAVAX.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines or vaccines. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo ter če ste pred kratkim prejeli ali pa boste morda prejeli drugo cepivo.
This effect was more prominent in the group of older subjects (≥70 years of age), where the risk of developing PHN after zoster was reduced to 10% in the vaccine group vs. 19% for the placebo group. 
Ta učinek je bil izrazitejši pri starejših osebah (≥ 70 let), kjer se je tveganje za pojav PHN po herpesu zostru v skupini, ki je prejela cepivo, zmanjšalo na 10 %, v skupini na placebu pa na 19 %.
The safety profile was generally similar to the Adverse Event Monitoring Substudy of the SPS. 
Varnostni profil je bil na splošno podoben kot v podštudiji spremljanja neželenih učinkov študije SPS.
ZOSTAVAX cannot be used to treat existing shingles or the pain associated with existing shingles. 
Cepiva ZOSTAVAX se ne more uporabljati za zdravljenje že obstoječega pasovca ali bolečine, ki je povezana z že obstoječim pasovcem.
ZOSTAVAX is available in packs of 1 or 10. 
Cepivo ZOSTAVAX je na voljo v pakiranjih po 1 ali 10.
Table 1: Adverse Reactions from Clinical Trial Experience and Post-Marketing Surveillance 
Preglednica 1: Neželeni učinki iz kliničnih preskušanj in iz obdobja trženja cepiva
Long-term effectiveness study in individuals 50 years of age or older In a large-scale ongoing US prospective observational cohort study of the long-term effectiveness of ZOSTAVAX, individuals 50 years of age or older at the time of vaccination are being followed for the occurrence of HZ and PHN using validated endpoints. 
Dolgoročne študije učinkovitosti pri posameznikih, starih 50 let ali več V obsežni prospektivni, opazovalni, kohortni študiji dolgoročne učinkovitosti cepiva ZOSTAVAX, ki poteka v ZDA, posameznike, v času cepljenja stare 50 let ali več, spremljajo glede pojavnosti HZ in PHN z uporabo validiranih končnih točk.